Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy.

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Gligorov, J.
Harris, L.
Kostler, W. J.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VAMC, Lebanon, PA USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Tenon Hosp, Paris, France
[6] Yale Univ, New Haven, CT 06520 USA
[7] Univ Hosp Vienna, Vienna, Austria
[8] Humboldt Univ, Berlin, Germany
[9] Biol Specialiste Ctr Lutte Contre, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3S / 3S
页数：1
相关论文
共 50 条
  • [41] Serum EGFr and HER-2/neu predicts poor survival in metastatic breast cancer
    Hamer, P. J.
    Jarosz, D. E.
    Leitzel, K.
    Ali, S. M.
    Demers, L.
    Evans, D. B.
    Chaudri-Ross, H. A.
    Lipton, A.
    Camey, W. P.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A168 - A168
  • [42] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
  • [43] Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy
    Montemurro, Filippo
    Donadio, Michela
    Clavarezza, Matteo
    Redana, Stefania
    Jacomuzzi, Maria Elena
    Valabrega, Giorgio
    Danese, Saverio
    Vietti-Ramus, Guido
    Durando, Antonio
    Venturini, Marco
    Aglietta, Massimo
    ONCOLOGIST, 2006, 11 (04): : 318 - 324
  • [44] Level of HER2 amplification correlates with response to trastuzumab-based therapy
    Nature Clinical Practice Oncology, 2008, 5 (2): : 68 - 68
  • [45] What is the role of HER-2/neu and trastuzumab (HERCEPTIN®) in lung cancer?
    Hirsch, FR
    Franklin, WA
    Bunn, PA
    LUNG CANCER, 2002, 36 (03) : 263 - 264
  • [46] Clinical use of the serum marker HER-2/NEU in patients with breast cancer
    Dalu, D.
    Cattaneo, M. T.
    Piazza, E.
    Piva, S.
    Gambaro, A.
    Tosca, N.
    Gabris, A.
    Filipazzi, V
    Esani, G.
    Somma, L.
    Sarnataro, C.
    Zambelli, S.
    Damiani, E.
    ANNALS OF ONCOLOGY, 2007, 18 : 45 - 45
  • [47] Profiling serum HER-2/NEU in prostate cancer
    Siampanopoulou, M.
    Galaktidou, G.
    Dimasis, N.
    Gotzamani-Psarrakou, A.
    HIPPOKRATIA, 2013, 17 (02) : 108 - 112
  • [48] HER-2/neu serum levels and menopausal status
    Bagli, L
    Dittadi, R
    Zancan, M
    Panzini, I
    Monti, F
    Ravaioli, A
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (01): : 69 - 70
  • [49] Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer
    Musolino, A.
    Naldi, N.
    Bortesi, B.
    Capelletti, M.
    Pezzuolo, D.
    Michiara, M.
    Missale, G.
    Laccabue, D.
    Zerbini, A.
    Camisa, R.
    Ardizzoni, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) : 119 - 120
  • [50] Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer
    Guiu, S.
    Gauthier, M.
    Coudert, B.
    Bonnetain, F.
    Favier, L.
    Ladoire, S.
    Tixier, H.
    Guiu, B.
    Penault-Llorca, F.
    Ettore, F.
    Fumoleau, P.
    Arnould, L.
    BRITISH JOURNAL OF CANCER, 2010, 103 (09) : 1335 - 1342
12345